SRC and Familial prostate cancer: We also demonstrated that the inhibition of prostate cancer Src activity by treatment with Src-Abl inhibitor Dasatinib resulted in the inhibition of GSK3 tyrosine 216 phosphorylation in prostate cancer cell lines subsequently inhibiting proliferation, survival and invasion in vitro and resulting in impaired tumor growth in vivo [13].